Stock PHARM PHARMING GROUP N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Pharming Group N.V.

Equities

PHARM

NL0010391025

Real-time Euronext Amsterdam
Other stock markets
 06:45:02 2024-04-26 am EDT 		5-day change 1st Jan Change
0.8985 EUR +1.99% Intraday chart for Pharming Group N.V. +1.99% -12.85%
Apr. 22 Pharming Group to Buy Back EUR123 Million of Bonds due 2025 MT
Apr. 18 Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 54% by 2026.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • Analyst opinion has improved significantly over the past four months.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
PHARMING GROUP N.V. Stock Pharming Group N.V.
-12.85% 636M
B-
NOVO NORDISK A/S Stock Novo Nordisk A/S
+25.11% 556B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.33% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.90% 331B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.95% 296B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+12.68% 233B
B+
NOVARTIS AG Stock Novartis AG
+5.27% 201B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-10.31% 193B
A+
PFIZER, INC. Stock Pfizer, Inc.
-12.26% 143B
C+
AMGEN INC. Stock Amgen Inc.
-6.47% 144B
C+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PHARM Stock
  4. Ratings Pharming Group N.V.